PTPN11 and epilepsy: We recently identified an accumulation of brain somatic PTPN11 alterations in low-grade epilepsy-associated brain tumors (LEAT) [23], the second largest lesion category in drug-resistant focal epilepsies amenable to neurosurgical treatment [6, 21].